Two federal lawmakers have introduced a bill seeking to apply the review requi | Two federal lawmakers have introduced a bill seeking to apply the review requirements of the Comprehensive Outbound Investment National Security (COINS) Act to investments in Chinese biotechnology.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
House bill aims to crack down on China biotech deals
In Washington, biotech's China hawks are winning the conversation
Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech
US lawmakers reveal policy to curb collaboration with Chinese biotech - Pharmaceutical Technology
美国两党议员推动立法，限制对华生物技术投资
Accelerating Targeted Gene Expression Analysis in Drug Development
A turning point for pancreatic cancer patients
The next tech war? Why biotech may become a new US-China battleground
As Akeso takes center stage at ASCO, China biotech industry cements its coming of age
As pro-life pressure ramps up on Trump, FDA is investigating safety of abortion pill: WSJ
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block…
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S.…
PhRMA and BIO mobilize against a wave of anti-China biotech bills in Congress as lawmakers move to curb US dealmaking with China.
The FDA's new path, the status of animal testing, and other biotech news from The Readout
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…
Bipartisan Michigan lawmakers unveil a bill subjecting US-China biotech deals to outbound investment screening, citing national…
